NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Buy this stock Free ALIM Stock Alerts $4.00 -0.21 (-4.99%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$3.95▼$4.2650-Day Range$3.25▼$4.2152-Week Range$1.30▼$4.38Volume105,052 shsAverage Volume81,554 shsMarket Capitalization$209.40 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alimera Sciences alerts: Email Address Alimera Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside62.5% Upside$6.50 Price TargetShort InterestHealthy0.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector394th out of 947 stocksPharmaceutical Preparations Industry186th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Alimera Sciences has a forecasted upside of 62.5% from its current price of $4.00.Amount of Analyst CoverageAlimera Sciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.23% of the outstanding shares of Alimera Sciences have been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently decreased by 57.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 3.8 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Alimera Sciences this week, compared to 2 articles on an average week.Search Interest2 people have searched for ALIM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r About Alimera Sciences Stock (NASDAQ:ALIM)Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Read More ALIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIM Stock News HeadlinesMarch 18, 2024 | msn.comMizuho downgrades Amylyx to Neutral after ALS trial setbackMarch 14, 2024 | americanbankingnews.comShort Interest in Alimera Sciences, Inc. (NASDAQ:ALIM) Decreases By 57.2%March 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 10, 2024 | realmoney.thestreet.comAlimera Sciences price target raised by $1 at H.C. Wainwright, here's whyMarch 9, 2024 | seekingalpha.comAlimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical TrialsMarch 8, 2024 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Alimera Sciences Inc Earnings CallMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 7, 2024 | investorplace.comALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023March 7, 2024 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsMarch 7, 2024 | globenewswire.comAlimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsMarch 6, 2024 | benzinga.comA Preview Of Alimera Sciences's EarningsMarch 6, 2024 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To ProfitabilityFebruary 29, 2024 | finance.yahoo.comAlimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate UpdateFebruary 10, 2024 | msn.comAlimera Sciences Launches 2024 Equity Inducement PlanFebruary 8, 2024 | finance.yahoo.comThe UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®January 25, 2024 | finance.yahoo.comAlimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years agoJanuary 4, 2024 | finance.yahoo.comAlimera Completes Recruitment for the Synchronicity StudyJanuary 2, 2024 | marketwatch.comAlimera Sciences Names Elliot Maltz Chief Financial OfficerJanuary 2, 2024 | markets.businessinsider.comAlimera Sciences Names Elliot Maltz To Succeed Russell Skibsted As CFOJanuary 2, 2024 | finance.yahoo.comAlimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 12, 2023 | finance.yahoo.comAlimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 8, 2023 | finance.yahoo.comAlimera Appoints Maggie A. Pax to Its Board of DirectorsOctober 31, 2023 | finance.yahoo.comAlimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of OphthalmologyOctober 27, 2023 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call TranscriptOctober 27, 2023 | markets.businessinsider.comAlimera Sciences Reports Third Quarter 2023 ResultsSee More Headlines Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/18/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees150Year Founded2003Price Target and Rating Average Stock Price Target$6.50 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+62.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E Ratio133.33 P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-24.93% Pretax Margin-24.83% Return on Equity-130.90% Return on Assets-10.22% Debt Debt-to-Equity Ratio1.40 Current Ratio2.39 Quick Ratio2.63 Sales & Book Value Annual Sales$80.75 million Price / Sales2.59 Cash FlowN/A Price / Cash FlowN/A Book Value($5.72) per share Price / Book-0.70Miscellaneous Outstanding Shares52,350,000Free Float35,915,000Market Cap$209.40 million OptionableOptionable Beta1.16 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Richard S. Eiswirth Jr. (Age 56)CEO & Director Comp: $597.87kMr. David R. Holland (Age 60)Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets Comp: $413.5kDr. Philip Ashman Ph.D. (Age 59)President of International Operations Comp: $389.86kMr. Todd Michael Wood (Age 54)President of U.S. Operations Mr. Elliot Maltz CPA (Age 39)CFO & Treasurer Mr. Jason WernerChief Operating OfficerChristopher S. VisickVP, General Counsel & SecretaryDr. David Dyer M.D.Chief Retina SpecialistMore ExecutivesKey CompetitorsOvid TherapeuticsNASDAQ:OVIDSpruce BiosciencesNASDAQ:SPRBAbeona TherapeuticsNASDAQ:ABEOGeneration BioNASDAQ:GBIORenovaroNASDAQ:RENBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 502,268 shares on 3/11/2024Ownership: 1.238%Vanguard Group Inc.Bought 502,268 shares on 2/15/2024Ownership: 1.238%Citadel Advisors LLCBought 19,874 shares on 2/15/2024Ownership: 0.038%Balyasny Asset Management L.P.Bought 40,032 shares on 2/14/2024Ownership: 0.076%Northern Trust CorpBought 14,132 shares on 2/13/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions ALIM Stock Analysis - Frequently Asked Questions Should I buy or sell Alimera Sciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks. What is Alimera Sciences' stock price target for 2024? 2 brokerages have issued 1 year target prices for Alimera Sciences' shares. Their ALIM share price targets range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 62.5% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts. How have ALIM shares performed in 2024? Alimera Sciences' stock was trading at $4.32 at the start of the year. Since then, ALIM stock has decreased by 7.4% and is now trading at $4.00. View the best growth stocks for 2024 here. Are investors shorting Alimera Sciences? Alimera Sciences saw a decline in short interest in February. As of February 29th, there was short interest totaling 118,600 shares, a decline of 57.2% from the February 14th total of 276,800 shares. Based on an average daily volume of 101,600 shares, the days-to-cover ratio is currently 1.2 days. View Alimera Sciences' Short Interest. When is Alimera Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ALIM earnings forecast. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.09. The biopharmaceutical company earned $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative trailing twelve-month return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter in the prior year, the firm earned ($0.54) EPS. When did Alimera Sciences' stock split? Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What guidance has Alimera Sciences issued on next quarter's earnings? Alimera Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB). Who are Alimera Sciences' major shareholders? Alimera Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.63%), AIGH Capital Management LLC (4.25%), Vanguard Group Inc. (1.24%), Vanguard Group Inc. (1.24%), Worth Venture Partners LLC (1.06%) and Balyasny Asset Management L.P. (0.08%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan. View institutional ownership trends. How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALIM) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.